Young Kwang Chae

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

Medicine, Oncology, Metastasis +9

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko et al. · The Lancet Oncology · 2019 · 537 citations · Full text

Medicine, Oncology, Pharmacology +15

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip Pravin Patel, Megan Othus, Young Kwang Chae et al. · Clinical Cancer Research · 2020 · 326 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)

Young Kwang Chae, Sangmin Chang, Taeyeong Ko et al. · Scientific Reports · 2018 · 258 citations · Full text

Medicine, Immunology, Oncology +17

Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins

Young Kwang Chae, Matías E. Valsecchi, Jong‐Oh Kim et al. · Cancer Investigation · 2011 · 182 citations

Medicine, Oncology, Pharmacotherapy +16